Abstract:Despite a generally better prognosis than high-grade glioma (HGG), recurrence and malignant progression are the main causes for the poor prognosis and difficulties in the treatment of low-grade glioma (LGG). It is of great importance to learn about the risk factors and underlying mechanisms of LGG recurrence and progression. In this study, the transcriptome characteristics of four groups, namely, normal brain tissue and recurrent LGG (rLGG), normal brain tissue and secondary glioblastoma (sGBM), primary LGG (pLGG) and rLGG, and pLGG and sGBM, were compared using Chinese Glioma Genome Atlas (CGGA) and Genotype-Tissue Expression Project (GTEx) databases. In this study, 296 downregulated and 396 upregulated differentially expressed genes (DEGs) with high consensus were screened out. Univariate Cox regression analysis of data from The Cancer Genome Atlas (TCGA) yielded 86 prognostically relevant DEGs; a prognostic prediction model based on five key genes (HOXA1, KIF18A, FAM133A, HGF, and MN1) was established using the least absolute shrinkage and selection operator (LASSO) regression dimensionality reduction and multivariate Cox regression analysis. LGG was divided into high- and low-risk groups using this prediction model. Gene Set Enrichment Analysis (GSEA) revealed that signaling pathway differences in the high- and low-risk groups were mainly seen in tumor immune regulation and DNA damage-related cell cycle checkpoints. Furthermore, the infiltration of immune cells in the high- and low-risk groups was analyzed, which indicated a stronger infiltration of immune cells in the high-risk group than that in the low-risk group, suggesting that an immune microenvironment more conducive to tumor growth emerged due to the interaction between tumor and immune cells. The tumor mutational burden and tumor methylation burden in the high- and low-risk groups were also analyzed, which indicated higher gene mutation burden and lower DNA methylation level in the high-risk group, suggesting that with the accumulation of genomic mutations and epigenetic changes, tumor cells continued to evolve and led to the progression of LGG to HGG. Finally, the value of potential therapeutic targets for the five key genes was analyzed, and findings demonstrated that KIF18A was the gene most likely to be a potential therapeutic target. In conclusion, the prediction model based on these five key genes can better identify the high- and low-risk groups of LGG and lay a solid foundation for evaluating the risk of LGG recurrence and malignant progression.

Downregulation of Neogenin in the Carcinogenesis and Progression of Glioma

Overexpression of NNMT in Glioma Aggravates Tumor Cell Progression: an Emerging Therapeutic Target.

Analysis and Significance of Nanog Promoter Methylation Status in Gliomas and Glioma Cells

NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma

Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter

Methylation Status of Promoter 1 Region of GDNF Gene in Human Glioma Cells.

Upregulation of the Long Non-Coding RNA SNHG1 Predicts Poor Prognosis, Promotes Cell Proliferation and Invasion, and Reduces Apoptosis in Glioma.

Promoter Methylation and Downregulation of SLC22A18 Are Associated with the Development and Progression of Human Glioma

Expression of neuropilin-1 is linked to glioma associated microglia and macrophages and correlates with unfavorable prognosis in high grade gliomas

GNAO1 Overexpression Promotes Neural Differentiation of Glioma Stem-Like Cells and Reduces Tumorigenicity Through TRIM21/CREB/HES1 Axis

MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma

MicroRNA-193a-5p exerts a tumor suppressor role in glioblastoma via modulating NOVA1

Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas

Pan-glioma analyses reveal species- and tumor-specific regulation of neuron-glioma synapse genes by lncRNAs

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy

GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma

Long non-coding RNA NEAT1 promotes human glioma tumor progression via miR-152-3p/CCT6A pathway

Genistin Represses the Proliferation and Angiogenesis While Accelerating the Apoptosis of Glioma Cells by Modulating the FOXC1-Mediated Wnt Signaling Pathway

Upregulation of Chemokine Receptor Ccr10 is Essential for Glioma Proliferation, Invasion and Patient Survival

Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma

NCAPG as a Novel Prognostic Biomarker in Glioma